miR-223 induces retinal ganglion cells apoptosis and inflammation via decreasing HSP-70 in vitro and in vivo.

PURPOSE: Glaucoma is an eye disease characterized by the loss of peripheral vision, high pressure in the eye, optic nerve damage, and the loss of peripheral vision due to loss of retinal ganglion cells (RGCs). A number of miRNA have been detected in the pathogenesis of glaucoma. The paper was to focus on the miR-223 in RGCs apoptosis and inflammation, and investigated the possible mechanisms in vitro and in vivo. MATERIALS AND METHODS: After miR-223 inhibitor and mimics transfected into RGCs, the expression of miR-223 was detected by QRT-PCR, cell proliferation were performed by CCK-8 and EdU assays, cell apoptosis were measured by flow cytometer and TUNEL assays, apoptosis and inflammation -related proteins were detected by western blot, and whether miR-223 target to HSP-70 was detected by Luciferease reporter assay. Moreover, the effects si-HSP-70 on RGCs or RGCs transfected with miR-223 inhibitor were detected. In vivo study. New Zealand White rabbits (20 females) were used to detect the effect of miR-223 on the rabbit glaucoma model induced by injection of carbomer. RESULTS: CCK-8 and EdU assays demonstrated that miR-223 mimics decreased RGCs proliferation. FITC-Annexin V/PI Apoptosis and TUNEL assays showed that miR-223 mimics induced RGCs apoptosis. Western blot revealed that miR-223 mimics enhanced the expression of relative apoptosis and inflammation factors. Further, we demonstrated that miR-223 could inhibit cell proliferation, induce cell apoptosis as well as inflammation by targeting HSP-70 in RGCs. Moreover, the results were confirmed in rabbit glaucoma model. CONCLUSIONS: In summary, miR-223 plays a vital role in RGCs by regulating HSP-70 expression, and the new therapeutic strategy might potentially contribute to benefit glaucoma treatment.

Shuxuetong injection combined with intravitreal injection of Ranibizumab and laser photocoagulation in the treatment of BRVO with macular edema / 国际眼科杂志(Guoji Yanke Zazhi)

AIM:To investigate the curative effect of Shuxuetong injection combined with intravitreal injection of ranibizumab and laser photocoagulation in the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).METHODS:Totally 70 patients (70 affected eyes) with ME secondary to BRVO treated from January 2015 to December 2016 were randomly divided into the control group and the observation group by random number table method,35 patients (35 affected eyes) in each group.The control group were treated by intravitreal injection of ranibizumab and laser photocoagulation,and on the basis,the observation group were treated with Shuxuetong injection.The clinical curative effect and complications were compared between the two groups.At 1wk,1 and 3mo after treatment,the best corrected visual acuity (BCVA) and central retinal thickness (CRT)were checked again.RESULTS:The total effective rate of treatment in the observation group was slightly higher than that in the control group (91％ vs 80％;P＞0.05) while the markedly effective rate in the observation group was higher than that in the control group (43％ vs20％;P＜0.05).At 1wk,1 and 3mo after treatment,BCVA and CMT in the two groups decreased (P＜0.05),and they were lower in the observation group than the control group at the same time point (P＜0.05).There was no significant difference in the incidence of complications between the two groups (P＞0.05).CONCLUSION:The treatment of ME secondary to BRVO with Shuxuetong injection combined with intravitreal injection of ranibizumab and laser photocoagulation can effectively reduce CRT and improve visual acuity,with high safety.